Rx-360 Selects BSI Supply Chain Solutions to Lead Its International Joint Audit Program
Rx-360 announces a strategic partnership with BSI Supply Chain Solutions on Rx-360’s Joint Audit Program designed to enhance patient safety and increase supply chain security through on-the-ground supplier audits.
One of the world’s leading business solutions providers, BSI shares in Rx-360’s commitment to patient safety with its long history ensuring quality and consistency.
BSI will work with Rx-360 to further streamline the audit process and ensure supplier compliance with quality and security standards through verification audits. Overall security will be strengthened through improved supply chain transparency and visibility.
Rx-360, a not-for-profit international consortium representing the world’s leading pharmaceutical and biotech organizations, is committed to protecting patient safety. Recognizing that the globalization of suppliers has added significant complexity to ensuring supplier quality and security of the supply chain, Rx-360 has developed the Joint Audit program to verify and validate supplier compliance, enhance supply chain integrity and improve quality.
This innovative approach will allow multiple companies working with the same business partner to participate in a standardized audit without sacrificing product or process confidentiality. This in turn will significantly reduce audit costs, standardize the audit scope, expand the number of audits conducted, and ultimately reduce supplier audit fatigue while maintaining a high quality standard. The Joint Audit program will ensure audit consistency and transparency from audit scheduling through the required Corrective and Preventive Actions.
BSI was selected for this engagement following a thorough RFP process that considered more than a dozen other highly-qualified auditing firms. Rx-360 has chosen a partner in BSI that has proven its commitment to patient safety through its extensive work in the medical device industry.
With more than 70,000 clients worldwide and more than 150,000 audit days in 150 countries per year, BSI has the resources and infrastructure required to assist Rx-360 with their audit needs and is perfectly positioned to serve as a partner with Rx-360 members’ supplier base.
BSI will utilize its Supplier Verification (VerifEYE) services which will provide local personnel familiar with the local language, customs and traditions to conduct the audits. To ensure consistency of audits, these auditors will be trained by BSI Supply Chain Solutions to standards specific to Rx-360 members’ auditing requirements, including cGMP regulations as well as supply chain security.
Dan Purtell, Senior Vice President, Supply Chain Solutions stated: “By incorporating BSI’s extensive history of corporate auditing, our reputation in the medical device community for patient-safety, and our cutting-edge risk-based approach to supply chain security, we are able to offer Rx-360 a unique solution to meet their needs for efficient and comprehensive supplier auditing. This award will help Rx-360 members significantly reduce ineffective and overlapping audits while maintaining the overarching goal of increasing patient safety.”
Ben Mills, Co-Chair of Rx-360’s Audit Operations Group stated: “Rx-360’s primary mission is to ensure patient safety by maintaining high standards of quality during the manufacturing process. The Joint Audit program will allow consortium members to pool resources and have third-party audits conducted simultaneously while protecting commercially-sensitive and proprietary information. With BSI Supply Chain Solutions, Rx-360 has a partner known for experience, confidentiality, and quality. BSI’s risk-based approach to auditing will enhance effectiveness and supply chain security. The Joint Audit Program offers consortium members, suppliers and manufacturers alike, the opportunity to reduce the audit burden while amplifying product confidence and safety.”
BSI’s integration into Rx-360’s Joint Audit program will begin later this summer.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.